The goal of the Mayo Clinic Center for Cell Signaling in Gastroenterology (C-SiG) is to connect discovery, translational, and patient-oriented investigators to enhance understanding and therapeutically exploit signaling pathways in gastrointestinal cells to improve the health of patients with digestive diseases. The Research Base consists of 59 scientists and $23 million (direct costs, 70% growth) in digestive disease related funding. C-SiG members are organized into three Mechanistic Research Themes: 1) Ion channels/membrane receptors;ii) Signal transduction;and, iii) Genetics and gene regulation. Our CENTRAL HYPOTHESIS is that advances in clinical care of patients with digestive diseases requires a facilitative infrastructure supporting meaningful interactions among multidisciplinary scientists investigating cellular mechanisms, pathways and therapeutic targets to enhance rapid translation of basic discoveries into clinical trials. C-SiG's OVERALL SPECIFIC AIMS are to: i) Foster multidisciplinary research by expanding technical and collaborative capabilities of established Gl scientists and attracting investigators from other disciplines;li) Develop and implement a robust Scientific Enrichment Program that includes seminars, workshops, symposia, a visiting faculty program, minisabbatical, and Web-based curricula;iii) Offer specialized equipment, technologies, methodologies, reagents, and expertise to assist C-SiG members through the C-SiG Cores, including: a) State-of-the-art microscopic technology and consultative expertise (Optical Microscopy Core);b) Accelerated and expanded biospecimen acquisition, processing, and annotation (Clinical Core);c) Emerging genetic technologies and model systems (Genetics and Model Systems Core);iv) Identify and nurture new Gl investigators via a peer-reviewed Pilot and Feasibility Program;v) Promote synergistic interactions between C-SiG members and other Gl investigators at Mayo and at other Gl centers to facilitate clinical trials resulting from the identification of cellular therapeutic tarets;vi) Share technologies with other NIDDK centers at Mayo (e.g., PKD Center) and existing Digestive Disease Research Core Centers, especially in the Midwest (i.e. Midwest DDRCC Alliance).

Public Health Relevance

Gastrointestinal diseases and their complications have a significant effect on public health and health care utilization costs. Research supported by this Center grant, is critically important for furthering understanding of the mechanisms that underlie digestive diseases, which can lead to practical applications for the diagnosis, prevention, monitoring and treatment of human disease

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Center Core Grants (P30)
Project #
2P30DK084567-06
Application #
8699451
Study Section
Special Emphasis Panel (ZDK1)
Program Officer
Grey, Michael J
Project Start
2009-09-01
Project End
2019-08-31
Budget Start
2014-09-01
Budget End
2015-08-31
Support Year
6
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
City
Rochester
State
MN
Country
United States
Zip Code
55905
Orozco, Carlos A; Martinez-Bosch, Neus; Guerrero, Pedro E et al. (2018) Targeting galectin-1 inhibits pancreatic cancer progression by modulating tumor-stroma crosstalk. Proc Natl Acad Sci U S A 115:E3769-E3778
Cipriani, Gianluca; Gibbons, Simon J; Miller, Katie E et al. (2018) Change in Populations of Macrophages Promotes Development of Delayed Gastric Emptying in Mice. Gastroenterology 154:2122-2136.e12
Razidlo, Gina L; Burton, Kevin M; McNiven, Mark A (2018) Interleukin-6 promotes pancreatic cancer cell migration by rapidly activating the small GTPase CDC42. J Biol Chem 293:11143-11153
Kostallari, Enis; Hirsova, Petra; Prasnicka, Alena et al. (2018) Hepatic stellate cell-derived platelet-derived growth factor receptor-alpha-enriched extracellular vesicles promote liver fibrosis in mice through SHP2. Hepatology 68:333-348
Bandla, Harikrishna; Dasgupta, Debanjali; Mauer, Amy S et al. (2018) Deletion of endoplasmic reticulum stress-responsive co-chaperone p58IPK protects mice from diet-induced steatohepatitis. Hepatol Res 48:479-494
Guicciardi, Maria Eugenia; Trussoni, Christy E; Krishnan, Anuradha et al. (2018) Macrophages contribute to the pathogenesis of sclerosing cholangitis in mice. J Hepatol 69:676-686
Mouchli, Mohamad A; Singh, Siddharth; Boardman, Lisa et al. (2018) Natural History of Established and De Novo Inflammatory Bowel Disease After Liver Transplantation for Primary Sclerosing Cholangitis. Inflamm Bowel Dis 24:1074-1081
Paradise, Brooke D; Barham, Whitney; Fernandez-Zapico, Martín E (2018) Targeting Epigenetic Aberrations in Pancreatic Cancer, a New Path to Improve Patient Outcomes? Cancers (Basel) 10:
Banales, Jesus M; Marzioni, Marco; LaRusso, Nicholas F et al. (2018) Cholangiocytes in health and disease: From basic science to novel treatments. Biochim Biophys Acta Mol Basis Dis 1864:1217-1219
Tarragó, Mariana G; Chini, Claudia C S; Kanamori, Karina S et al. (2018) A Potent and Specific CD38 Inhibitor Ameliorates Age-Related Metabolic Dysfunction by Reversing Tissue NAD+ Decline. Cell Metab 27:1081-1095.e10

Showing the most recent 10 out of 537 publications